Vita 34 AG, DE000A0BL849

Vita 34 AG, DE000A0BL849

22.11.2022 - 15:54:29

EQS-News: Vita 34 benefits from increasing normalization in its core business in the third quarter

EQS-News: Vita 34 AG

/ Key word(s): 9 Month figures

Vita 34 benefits from increasing normalization in its core business in the third quarter

22.11.2022 / 15:51 CET/CEST

The issuer is solely responsible for the content of this announcement.

Vita 34 benefits from increasing normalization in its core business in the third quarter

Revenues for the first nine months rose to EUR 50.8 million; business development gains further momentum in the third quarter EBITDA of EUR -1.6 million in the first nine months below previous year due to continued investments in the new activities, but already clearly positive again in the third quarter Outlook for the full year 2022 confirmed

Leipzig, 22 November 2022 - Against the backdrop of a still difficult economic environment, Vita 34 AG (ISIN: DE000A0BL849; WKN: A0BL84), the leading cell bank in Europe and third largest in the world, continues to lag behind its potential in its development so far in the current fiscal year. At the same time, however, there were signs of a further normalization of business development in the third quarter, accompanied by a noticeable improvement in the revenue and earnings situation at quarterly level.

As a result of the merger with PBKM FamiCord, revenues in the first nine months were again significantly higher than in the previous year at EUR 50.8 million (9M 2021: EUR 16.1 million). In contrast to the restrained business development in the first half of 2022, which was largely characterized by a clearly perceptible decline in demand from new customers as a result of the Omicron wave and the Ukraine conflict, the normalization of business development that had been apparent since June continued in the third quarter. Earnings before interest, taxes, depreciation and amortization (EBITDA) were still significantly lower year-on-year at EUR -1.6 million (9M 2021: EUR 3.1 million), partly due to further investments in the newly emerging activities and in R&D. However, against the backdrop of the resurgence in business development and lower cost of sales due to strict cost control, EBITDA in the third quarter was already back in clearly positive territory at EUR 1.0 million, although not yet at the level of the comparable period of the previous year (Q3 2021: EUR 1.5 million).

"2022 is without question a tough year for us. The restrictions imposed by COVID-19 and Russia's attack on Ukraine, which caused energy prices and inflation to rise abruptly, have acted as a psychological brake on signing a contract for many of our potential customers," says Jakub Baran, CEO of Vita 34 AG. "The new cost pressure on living expenses is very real for many of our customers. Therefore, it is only understandable that expectant parents first have to get used to the new spending levels until they can again mentally consider the unique opportunity that stem cell storage offers at the birth of their child. This normalization of demand is slowly emerging, but it appears to be sustainable."

The key figures for business development are as follows:

? IFRS, in EUR ?000 Q3 Q3 9M 9M 9M ? ? ? 2022 2021* 2022 2021* ? ? ? Revenues ???? 18,655 ?????? 5,646 ???? 50,764 ???? 16,111 215.1% ? ? Gross profit ?????? 5,987 ?????? 3,404 ???? 13,409 ?????? 9,419 42.4% ? ? EBITDA ?????? 1,008 ?????? 1,486 -1,606 ?????? 3,137 -151.2% ? ? EBITDA margin [%] 5.4% 26.3% -3.2% 19,5% ? ? ? EBIT -1,111 ????????? 828 -7,976 ????????? 954 -936.0% ? ? Result for the period -386 ????????? 444 -8,058 ????????? 132 -6,188,9% ? ? Earnings per share [in EUR] -0.02 ???????? 0.11 -0.50 ???????? 0.03 -1,766,7% ? ? Operating cash flow -3,219 ?????? 2,390 -289.3% ? ? Cash & cash equivalents (vs. 31 Dec. 2021) ???? 19,804 ???? 33,298 -40.5% ? ? *Prior-year figures adjusted. The adjustments are explained in Note 2.3 of the Annual Report 2021. ? ?

22.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at www.eqs-news.com

Language: English Company: Vita 34 AG Deutscher Platz 5a 04103 Leipzig

Germany Phone: +49(0341)48792-40 Fax: +49(0341)48792-39 E-mail: ir@vita34.de Internet: www.vita34.de ISIN: DE000A0BL849 WKN: A0BL84 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1492745 ? End of News EQS News Service

1492745??22.11.2022?CET/CEST

@ dgap.de